Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 2, 2006

Gladstone Institutes and Merck & Co. Establish Apolipoprotein Collaboration

  • The J. David Gladstone Institutes and Merck & Co. inked a major collaboration and license agreement for research and development of drugs to treat neurodegenerative diseases, such as Alzheimer's disease, which are linked to apoE-regulated mechanisms in the body.

    The agreement provides Merck, through an affiliate, a worldwide, exclusive license to research, develop, and commercialize compounds that are directed to apoE-regulated pathways and result from collaborative research or discoveries that have been made in the field of neurodegeneration by the Gladstone Institutes. The agreement also establishes a four-year research collaboration with the research team led by Robert W. Mahley, M.D., Ph.D., president of the Gladstone Institutes.

    Under the terms of the agreement, Gladstone will receive a $3.25-million upfront payment, significant milestone fees, and an annual license fee in addition to downstream royalties on any marketed products that result from the agreement.
    For at least four years, Gladstone will also receive funding for apoE research conducted at the Gladstone Institutes' new Center for Translational Research.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »